ALGS
Aligos Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$4.84
−0.41%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$5.03
From 52W high−63.61%
Volume82008.00
Market cap$30.22M
P/E (TTM)—
P/S (TTM)1.0x
Div yield—
Key dataOct 19, 2026
Open
$5.03
From 52W high
−63.61%
Volume
82008.00
Market cap
$30.22M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.0x
P/E (TTM)
—
RSI (14)
37.9
MomentumView details →
1D Return
−0.41%
YTD Return
−46.78%
SummaryUpdated Jun 1, 2026
Aligos Therapeutics, Inc. (NASDAQ:ALGS) is a clinical-stage biopharmaceutical company founded in 2018 and headquartered in South San Francisco, California. The company went public in October 2020 and focuses on developing novel therapeutics to address unmet medical needs in viral and liver diseases. Since its inception, Aligos has built a pipeline of drug candidates targeting chronic hepatitis B and non-alcoholic steatohepatitis (NASH), with several compounds currently in various phases of clinical trials.
Similar companies
Latest newsMore news →
Aligos Therapeutics announced that five abstracts were accepted for presentation at the American Association for the Study of Liver Disease's The Liver Meeting 2026, to be held November 5-9, 2026 in Denver, Colorado.14d agoAligos Therapeutics amended its lease with Britannia Biotech Gateway Limited Partnership, extending the term to March 31, 2034 with escalating rent, a 10-month abatement, and an early termination option.34d ago